Brian Skorney
Stock Analyst at Baird
(3.84)
# 729
Out of 5,044 analysts
117
Total ratings
48.81%
Success rate
10.93%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $10 → $16 | $14.04 | +13.96% | 3 | Oct 20, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $42.90 | +44.52% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $18.11 | +187.13% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $23.45 | +49.25% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $69.95 | +72.98% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $23.63 | +35.42% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $147.86 | +72.46% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $652.91 | -10.09% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $70.46 | -21.94% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $118.50 | -15.61% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $16.17 | +85.53% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $1.22 | +309.84% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $10.63 | +88.15% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.71 | +430.79% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $291.77 | -26.31% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $138.02 | +30.42% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $9.91 | +182.54% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $12.84 | +203.74% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $42.30 | +48.94% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $417.21 | -22.10% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $21.65 | -53.81% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $3.96 | +6,718.18% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.61 | +30.15% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.50 | +19,900.00% | 3 | May 7, 2018 |
Alto Neuroscience
Oct 20, 2025
Maintains: Outperform
Price Target: $10 → $16
Current: $14.04
Upside: +13.96%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $42.90
Upside: +44.52%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $18.11
Upside: +187.13%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $23.45
Upside: +49.25%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $69.95
Upside: +72.98%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $23.63
Upside: +35.42%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $147.86
Upside: +72.46%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $652.91
Upside: -10.09%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $70.46
Upside: -21.94%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $118.50
Upside: -15.61%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $16.17
Upside: +85.53%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $1.22
Upside: +309.84%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $10.63
Upside: +88.15%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.71
Upside: +430.79%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $291.77
Upside: -26.31%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $138.02
Upside: +30.42%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $9.91
Upside: +182.54%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $12.84
Upside: +203.74%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $42.30
Upside: +48.94%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $417.21
Upside: -22.10%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $21.65
Upside: -53.81%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $3.96
Upside: +6,718.18%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.61
Upside: +30.15%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.50
Upside: +19,900.00%